Negative in Ames, in vitro CHO chromosomal aberration and rat micronucleus assays
“Fedratinib was not mutagenic in a bacterial reverse mutation (Ames) assay, or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or in vivo in a micronucleus test in rats.”
✓ VerifiedFDA multi-discipline review, p. 59Source ↗
Carcinogenicity
6-month Tg.rasH2 mouse: no drug-related neoplasms; no 2-year rat study
“In a 6-month carcinogenicity study in transgenic Tg.RasH2 mice, there were no neoplasms that were attributed to treatment with fedratinib. No 2-year carcinogenicity study in rats was performed.”
Rat fertility: no remarkable effects; rat EFD: maternal toxicity at mid and high doses
“There were no remarkable fedratinib‐related effects in the FEED study. In the EFD study in rats, fedratinib was maternally toxic at the middle and high dose levels with lower gestational body weight gain and decreased gravid uterine weights.”
✓ VerifiedFDA multi-discipline review, p. 60Source ↗
Safety pharmacology
No significant cardiovascular or respiratory effects in dogs; no clear CNS effects in rats (non-dose-dependent miosis)
“In vivo, fedratinib was not associated with toxicologically significant effects on cardiovascular or respiratory parameters in dogs. There were no clear drug‐related CNS effects in rats; eye miosis and lack of pupillary responses were observed but were non‐dose‐dependent.”
✓ VerifiedFDA multi-discipline review, p. 58Source ↗
Not genotoxic overall: Ames negative; in vitro chromosome aberration positive without (not with) metabolic activation; rat micronucleus and comet negative